Adenosine

As a commonly used anti-arrhythmic and diagnostic adjuvant drug in clinical practice, adenosine is a purine endogenous nucleoside. By activating A1 adenosine receptors on cardiomyocytes, it slows down atrioventricular node conduction and inhibits sympathetic excitation, thereby rapidly terminating paroxysmal supraventricular tachycardia. Meanwhile, its transient negative inotropic and vasodilatory effects are also applied in the drug induction sessions of echocardiography stress testing and myocardial perfusion imaging. Its applicable population covers emergency patients with paroxysmal supraventricular tachycardia and subjects undergoing non-invasive diagnosis of coronary heart disease, making it an indispensable short-acting drug in the field of cardiovascular diagnosis and treatment.

According to public data, the global market size of adenosine drugs has maintained steady growth in recent years, reaching approximately USD 1.27 billion in 2023 with a compound annual growth rate of around 4.8%, among which the growth rate of adenosine preparations for diagnostic use is slightly higher than that of anti-arrhythmic dosage forms. In terms of the domestic market, generic drugs currently account for more than 90% of the market share, and leading manufacturers are concentrated in East China and South China. With the increase in the penetration rate of cardiovascular diagnosis and treatment, the annual domestic demand for adenosine API has exceeded 200 tons. Moreover, the decline in preparation prices after the implementation of the centralized procurement policy has further driven the expansion of demand for upstream API.

The original developer of adenosine is Baxter International Inc. of the United States, with the brand name Adenocard. The core compound patent expired globally in 1997. At present, the main marketed dosage form is injection, with specifications including 2ml:6mg and 4ml:12mg. This original dosage form has been included in the FDA Reference Listed Drug Catalog, and is also included in the *Catalog of Reference Preparations for Chemical Drugs* of China. Up to now, there have been 12 valid registration numbers for adenosine API on the API registration platform of the Center for Drug Evaluation of China, among which 7 are in Status A. More than 20 domestic enterprises have obtained approval for marketing of adenosine injection, and the domestic supply system for API is mature. (Data as of November 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for adenosine API, covering all research dimensions such as process impurities and degradation impurities. Most products are in stock, and spot orders placed before 16:00 can be shipped on the same day. All reference standards meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the technical needs of different scenarios such as API R&D, quality research, and declaration and registration.